MyMD reports statistically significant results from phase 2 trial for sarcopenia/age-related frailty
Betsy Goodfellow | August 2, 2023 | News story | Research and Development | Musculo-skeletal disorder, MyMD, clinical trial, sarcopenia
MyMD Pharmaceuticals has announced statistically significant positive topline results from a phase 2 trial of oral TNF- α inhibitor, MYMD-1 in patients with chronic inflammation associated with sarcopenia or age-related frailty.
The trial met its primary endpoints meaning it significantly reduced chronic inflammatory markers in patients treated with MYMD-1. The drug now has the potential to become the first drug approved by the US Food and Drug Administration (FDA) for the treatment of sarcopenia.
Sarcopenia is an age-related decline in physical function which can lead to an increased risk of hospitalisation, disability and, ultimately, death.
Chris Chapman, MD, president, director and chief medical officer at MyMD, commented: “We are very excited about these results indicating MYMD-1 demonstrated statistically significant reductions in all three inflammatory markers and met all additional pharmacokinetic and safety endpoints needed to advance our sarcopenia clinical programme, with guidance from the FDA. These results support the unique advantages of MYMD-1 as the first oral, selective TNF-α inhibitor candidate and potential future treatment option for sarcopenia and other autoimmune conditions such as rheumatoid arthritis. […] We are encouraged by the reduction of inflammatory markers along with the favorable safety profile demonstrated in this study of an oral TNF-α inhibitor. Sarcopenia can significantly affect people as they age, and there are currently no approved treatments for the condition. A selective, oral treatment that reduces TNF-α and inflammation and does not require infusion or injection would be a welcome advance for this population.”
Full results of the study are expected to be published at a later date.
Betsy Goodfellow
Related Content
SMC accepts atogepant for acute migraine treatment in Scotland
The Scottish Medicines Consortium (SMC) has accepted AbbVie’s Aquipta (atogepant) as an option for the …
Amphista doses first patient in AML trial of protein degrader
Amphista Therapeutics has dosed the first patient in a phase 1 trial of AMX-883, an …
Tridem begins phase Ib trial of Parkinson’s disease vaccine
Tridem Bioscience has enrolled the first patients in a phase Ib clinical trial of TRB-001, …
